UBS Raises Alkermes' Rating to Buy, Increases Target Price to $42

Summary

UBS has upgraded Alkermes from a neutral to a buy rating and adjusted the target price from $33.00 to $42.00. Alkermes is a biotechnology company focused on developing and commercializing drugs to meet unmet medical needs, operating in the US, Ireland, and other regions, with the main revenue source from the US market.

Impact Analysis

The event is classified at the company level as it specifically pertains to UBS’s reassessment of Alkermes’ stock. The direct impact of UBS upgrading Alkermes’ rating and increasing its target price to $42.00 is likely to be positive for the stock price in the near term, as investors might perceive this as a vote of confidence in the company’s prospects. This is reinforced by other analysts’ actions: Needham has also set a buy rating with a target price of $45.00, and Robert W. Baird has a target price of $41.00 with an outperform rating.Benzinga+ 2 The average analyst target price for Alkermes is approximately $39.93, indicating a general positive sentiment around the stock.Trading View These ratings suggest potential for upward price movement, making Alkermes an attractive opportunity for investors seeking exposure in the biotechnology sector. Second-order effects might include increased interest from institutional investors and enhanced liquidity for the stock.